Search Results for covid-19

Clinical trials and post-trial monitoring show that COVID-19 vaccines reduce the spread and occurrence of the disease

The COVID-19 vaccines authorized for emergency use by the U.S. Food and Drug Administration have demonstrated their safety and effectiveness at preventing the disease. Estimations for the lethality of a disease cannot be extrapolated to individuals, since the probability of an individual dying from a disease depends on their own characteristics, such as age and preexisting conditions.

COVID-19 related deaths are indeed caused by COVID-19 and not by contributing health conditions

Underlying cause of death is defined as a medical condition that triggers a chain of clinical events that leads to the death of a patient. Contributing medical conditions can either be a consequence of that underlying cause of death or a pre-existing condition that weakens a patient’s resistance to injuries or diseases and indirectly contributes to their death. COVID-19 is the underlying cause of death in the large majority of recorded COVID-19 related deaths.

The mRNA COVID-19 vaccines aren’t operating systems, and won’t transform the human body into a virus-making factory

The COVID-19 mRNA vaccines are substances that stimulate the immune systems of vaccinated individuals to recognize and respond to infections with SARS-CoV-2, the virus that causes COVID-19. COVID-19 mRNA vaccines aren’t computer operating systems. mRNA vaccines are unable to stimulate the production of the virus that causes COVID-19, since they only carry information to produce the spike protein, which is present on the surface of SARS-CoV-2.

Not all coronaviruses are seasonal, contrary to pathologist Ryan Cole’s claim; COVID-19 vaccines are effective at preventing illness

Not all coronaviruses exhibit seasonal activity. While common cold coronaviruses are seasonal, the viruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) aren’t seasonal. Data from clinical trials and the ongoing vaccination campaigns show that the COVID-19 vaccines are effective at reducing the risk of illness. While they commonly cause side effects such as fever, headache, and soreness, these are mild and short-lived. The benefits of COVID-19 vaccines far outweigh their risks, when compared to the risks associated with COVID-19.

COVID-19 vaccines don’t hamper the function of the immune system and are likely to limit the generation of variants; no evidence that they produce more lethal variants

Data from clinical trials showed that COVID-19 vaccines are effective and safe. The available evidence indicates that people vaccinated against COVID-19 are protected from the disease and maintain functional immune systems. Virus variants emerge as the virus infects more people and acquires new mutations during the process of making more copies of itself. Because COVID-19 vaccines can prevent individuals from viral infections, they prevent the virus from spreading and limit the opportunity for new variants to emerge.

COVID-19 vaccines received Emergency Use Authorization from the FDA after clinical trials demonstrated that they are safe and effective; COVID-19 vaccines aren’t experimental

Emergency Use Authorization (EUA) is a fast-track process for approving vaccines and drugs when their benefits outweigh the potential risks to a population. EUA is well-suited for addressing ongoing global health threats, such as the COVID-19 pandemic. Three COVID-19 vaccines received EAU from the FDA, after clinical data showed they were effective at protecting vaccinated individuals against the disease and had few risks for the general population. Continued monitoring of vaccinated populations is a standard procedure to increase our knowledge about a vaccine’s benefits and risk in a real world setting.

Clinical trials showed that the Moderna COVID-19 vaccine is safe; its side effects are mostly mild

The Moderna COVID-19 vaccine may cause mild and short-lived side effects such as fever, headache or fatigue. None of these effects have long-lasting consequences. Severe allergic reactions to the vaccine may occur, but these are rare and can be treated. Vaccination has been effective in eradicating polio from the vast majority of developing countries, preventing an estimated 16 million cases and 1.5 million deaths worldwide. While vaccine-derived polio cases do occur, they are very rare and can be avoided by improving sanitation and vaccine coverage in vulnerable communities.

COVID-19 vaccines are critical for controlling the pandemic; vaccines still offer partial protection against new variants of the virus

Emerging variants of the virus that causes COVID-19, some of which are more transmissible, have led to speculation about the efficacy of current COVID-19 vaccines. Emerging variants are subject to continuous monitoring to evaluate their potential impact on COVID-19 transmission and disease outcomes. The evidence so far indicates that COVID-19 vaccines still confer partial protection against these variants. Furthermore, the COVID-19 vaccines in use can be rapidly modified, and manufacturers are already anticipating new vaccine formulations to improve their efficacy against the new variants.

Ivermectin isn’t a highly effective drug for treating COVID-19

Scientific evidence doesn’t support the use of ivermectin as a treatment for COVID-19. Clinical trials must be designed and executed appropriately to show the efficacy and safety of a given drug for treating a particular disease. Clinical trials that show beneficial effects of using ivermectin to treat COVID-19 patients often have many methodological shortcomings and design flaws. More recent, well-designed studies show that ivermectin is ineffective for treating COVID-19 patients. Furthermore, safety data regarding ivermectin’s antiparasitic use doesn’t apply to its safety in COVID-19 patients.